Press release Communiqué de presse

Share the news     Partagez les nouvelles

Press release Communiqué de presse

November 16, 2021 16 November, 2021

Sernova to Present at the Canaccord Genuity Virtual MedTech, Diagnostics and Digital Health & Services Forum

November 16, 2021 6:00 AM ET

LONDON, ON – November 16, 2021 -- Sernova Corp. (TSX-V:SVA)(FSE/XETRA:PSH)(OTCQB:SEOVF), a leading clinical-stage company focused on regenerative medicine therapeutics, today announced that Dr. Philip Toleikis, President and CEO, will present at the Canaccord Genuity Virtual MedTech, Diagnostics and Digital Health & Services Forum on Thursday, November 18th, 2021 at 10:00am ET.

Management will be available throughout the conference for virtual one-on-one meetings. Investors interested in arranging a meeting with the Company’s management during the conference should contact the Canaccord Genuity conference coordinator or Sernova investor relations.

Webcast Information: A live webcast of Sernova’s presentation session will be available under ‘Featured News’ on the Company’s website at https://www.sernova.com/press or by accessing the event directly at following link: https://wsw.com/webcast/canaccord61/sva.v/2570694.

ABOUT SERNOVA Sernova is developing regenerative medicine therapeutic technologies using an implantable medical device and immune protected therapeutic cells (i.e. human donor cells, corrected human cells and stem cell-derived cells) to improve the treatment and quality of life of people with chronic metabolic diseases such as insulin- dependent diabetes, blood disorders including hemophilia, and other diseases treated through replacement of proteins or hormones missing or in short supply within the body. For more information, please visit www.sernova.com.

FOR FURTHER INFORMATION, PLEASE CONTACT:

Investors: Corey Davis, Ph.D. LifeScience Advisors, LLC cdavis@lifesciadvisors.com 212-915-2577

Corporate: Sernova Corp. 519-858-5126 investorrelations@sernova.com www.sernova.com

FORWARD-LOOKING INFORMATION This release contains statements that, to the extent they are not recitations of historical facts, may constitute “forward-looking statements” that involve various risks, uncertainties, and assumptions, including, without limitation, statements regarding the prospects, plans, and objectives of the company. Wherever possible, but not always, words such as "expects", "plans", "anticipates", "believes", "intends", "estimates", "projects", "potential for" and similar expressions, or that events or conditions "will", "would", "may", "could" or "should" occur are used to identify forward-looking statements. These statements reflect management’s beliefs with respect to future events, including results of clinical trials, and are based on information currently available to management on the date such statements were made. Many factors could cause Sernova’s actual results, performances, or achievements to not be as anticipated, estimated or intended or to differ materially from those expressed or implied by the forward-looking statements contained in this news release. Many of the factors are beyond our control, including those caused by, related to, or impacted by the novel coronavirus pandemic. Investors should consult the company’s quarterly and annual filings available on www.sedar.com for additional information on risks and uncertainties relating to the forward-looking statements. Sernova expressly disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.